Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

Pfizer climbs on strong Q3 results, raised outlook

Por: MarketWatch Business November 01, 2022

thumbnail

Pfizer’s CFO David Denton cited strong performance from the company’s Paxlovid and Eliquis products, particularly in the U.S., as well as the “continued impressive launch” of the Prevnar 20 vaccine for adults in the U.S.  Paxlovid is an antiviral used to treat COVID-19, while Eliquis is a blood thinner used to prevent blood clots. Prevnar 20 protects against pneumococcal bacteria. Third-quarter Paxlovid was $7.5 billion, against a... + full article



Similar News

Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics

CNBC USA Health November 02, 2022

thumbnailPfizer CEO Albert Bourla talks during a press conference with European Commission President after a visit to oversee the production of the Pfizer-BioNtech Covid-19 vaccine at the factory of US pharmaceutical company Pfizer, in Puurs, on April 23, 2021.John Thys AFP Getty Images... + más

Pfizer raises 2022 earnings guidance, beats third-quarter expectations | CNBC

Pfizer climbs on strong Q3 results, raised outlook | MarketWatch


When Will the RSV Vaccine be Available? Pfizer Jab Shows 'Positive' Results

Newsweek USA Health November 02, 2022

thumbnailPfizer announced positive trial results on Tuesday for a vaccine designed to help protect against the respiratory syncytial virus, or RSV, potentially setting up the company to have the first shot of its kind to be approved against the virus.The exact timeline for the vaccine... + más

Strong RSV vaccine data lifts hopes after years of futility | 10 WBNS

Pfizer says study shows vaccinating pregnant women protects newborns from RSV | ABC7


Pfizer climbs on strong Q3 results, raised outlook

MarketWatch USA Business November 01, 2022

thumbnailPfizer’s CFO David Denton cited strong performance from the company’s Paxlovid and Eliquis products, particularly in the U.S., as well as the “continued impressive launch” of the Prevnar 20 vaccine for adults in the U.S.  Paxlovid is an antiviral used to treat COVID-19,... + más

Pfizer climbs on strong Q3 results, raised outlook | MarketWatch

Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics | CNBC


Pfizer rides Paxlovid sales to better-than-expected quarter

ABC News USA Business November 01, 2022

thumbnailPfizer’s COVID-19 treatment helped the pharmaceutical giant balance tumbling international sales for its vaccine and top third-quarter expectations.The pill treatment Paxlovid brought in $7.5 billion in sales in the quarter and has generated more than $17 billion so far this... + más

Covid-19 treatment Paxlovid can interact with common heart medications, doctors warn | CNN

Pfizer raises 2022 earnings guidance, beats third-quarter expectations | CNBC


Pfizer raises 2022 earnings guidance, beats third-quarter expectations

CNBC USA Health November 01, 2022

thumbnailIn this articleVials containing the Pfizer/BioNtech vaccine against the coronavirus disease (COVID-19) are displayed before being used at a mobile vaccine clinic, in Valparaiso, Chile, January 3, 2022.Rodrigo Garrido Reuters on Tuesday raised its 2022 earnings guidance after... + más

Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics | CNBC

Pfizer climbs on strong Q3 results, raised outlook | MarketWatch


Moderna sues Pfizer over patents behind COVID-19 vaccine

The Advocate USA Crime October 10, 2022

thumbnailvaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main competitors of copying Moderna’s technology in order to make their own vaccine.Moderna said Friday that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed... + más

Moderna is suing Pfizer over its coronavirus vaccine | The Verge

Moderna vs Pfizer: Is it OK to mix and match the updated COVID-19 booster shots? | Los Angeles Times


Moderna is suing Pfizer over its coronavirus vaccine

The Verge USA Health September 24, 2022

thumbnailModerna is suing Pfizer over its coronavirus vaccineModerna is suing Pfizer over its coronavirus vaccine / The company is filing patent infringement lawsuits against Pfizerp>span:first-child]:text-black text-blurple>By Aug 26, 2022, 12:37 PM UTC Share this story... + más

Moderna vs Pfizer: Is it OK to mix and match the updated COVID-19 booster shots? | Los Angeles Times

Moderna vs. Pfizer: Is it OK to mix and match the updated COVID-19 booster shots? | PennLive



About iurex | Privacy Policy | Disclaimer |